11.3 Neurogenic Lower Urinary Tract Dysfunction (NLUTD)

11.3 Neurogenic Lower Urinary Tract Dysfunction (NLUTD)

Neurogenic Lower Urinary Tract Dysfunction (NLUTD) encompasses any disturbance of normal bladder storage and emptying resulting from documented central or peripheral nervous system disease. Management of NLUTD requires deep understanding of micturition neuroanatomy and urodynamic pathophysiology, with an unwavering commitment to protecting upper urinary tract renal function.

---

1. Neuroanatomy of Normal Micturition

Coordinated storage and evacuation of urine requires precise integration between the somatic and autonomic nervous systems across multiple central axes:

                                [ FRONTAL CORTEX ]
                          (Tonic Inhibitory Control)
                                     │
                                     ▼
                        [ PONTINE MICTURITION CENTER ]
                            (PMC / Barrington's)
                                     │
         ┌───────────────────────────┼───────────────────────────┐
         ▼                           ▼                           ▼
  [ SYMPATHETIC ]            [ PARASYMPATHETIC ]             [ SOMATIC ]
    (T10–L2)                      (S2–S4)                      (S2–S4)
  Hypogastric Nerve             Pelvic Nerves               Pudendal Nerve
         │                           │                           │
   β3: Relaxes Body            M2/M3: Contracts            Nicotinic: Striated
   α1: Closes Neck                Detrusor                   Sphincter Contraction
   [STORAGE PHASE]             [VOIDING PHASE]               [CONTINENCE]

Central Integration Centers

• Frontal Cortex & Anterior Cingulate Gyrus: Exert tonic inhibitory control over downstream brainstem voiding centers, maintaining continence during social activities.
• Periaqueductal Gray (PAG): Serves as the critical sensory relay station, transmitting ascending bladder fullness signals from the spinal cord to higher cortical centers.
• Pontine Micturition Center (PMC / Barrington's Nucleus): Located in the rostral pons; coordinates the reciprocal relaxation of the urethral sphincter and sustained contraction of the detrusor muscle during voluntary micturition.

Peripheral Efferent Innervation

1. Sympathetic System (T10–L2): Originates in the intermediolateral cell column; travels via lumbar splanchnic and hypogastric nerves to the pelvic plexus.
   • $\beta_3$-Adrenergic Receptors: Located in the detrusor body; norepinephrine stimulates active smooth muscle relaxation to accommodate filling (storage).
   • $\alpha_1$-Adrenergic Receptors: Concentrated at the bladder neck and preprostatic urethra; stimulates active smooth muscle contraction to maintain continence.
2. Parasympathetic System (S2–S4): Originates in the sacral parasympathetic nucleus; travels via pelvic splanchnic nerves.
   • Muscarinic Receptors ($M_2$ and $M_3$): Acetylcholine released from postganglionic parasympathetic fibers drives robust detrusor smooth muscle contraction during voiding ($M_3$ mediates active contraction, while $M_2$ inhibits sympathetically mediated relaxation).
3. Somatic System (S2–S4): Originates in the ventral horn motor neurons of Onuf's nucleus; travels via the pudendal nerve.
   • Releases acetylcholine onto nicotinic receptors of the striated external urethral sphincter (rhabdosphincter) and levator ani, providing voluntary, fast-response closure.

---

2. Neurological Lesion Levels & Urodynamic Consequences

Lesion level suggests a typical urodynamic pattern; assess the actual bladder and outlet function rather than inferring it from the neurological diagnosis alone:

1. Suprapontine Lesions

• Etiologies: Cerebrovascular accident (stroke), Parkinson's disease, normal pressure hydrocephalus, frontal brain tumors, traumatic brain injury.
• Pathophysiology: Disruption of inhibitory frontocortical pathways upstream of the PMC. The coordinating axis between the pons, spinal cord, and peripheral nerves remains anatomically intact.
• Urodynamic Pattern: Detrusor Overactivity (DO) with Coordinated Sphincter Relaxation.
• Clinical Presentation & Risk: Urgency, frequency, and urgency urinary incontinence. Upper-tract risk is generally lower than in high-pressure spinal NLUTD when storage and emptying remain safe.

2. Suprasacral Spinal Cord Lesions

• Etiologies: Traumatic spinal cord injury (SCI; cervical or thoracic), multiple sclerosis (MS), transverse myelitis, spinal tumors.
• Pathophysiology: Loss of descending regulatory pathways connecting the PMC to the sacral parasympathetic nucleus and Onuf's nucleus.
• Urodynamic Pattern: Detrusor Overactivity (DO) combined with Detrusor Sphincter Dyssynergia (DSD).
• Clinical Danger: Involuntary detrusor contractions occur against an involuntarily contracting, closed striated external urethral sphincter. Sustained high pressures and poor compliance can lead to vesicoureteral reflux (VUR), bladder diverticula, hydronephrosis, and renal deterioration; no particular pressure spike is required for this risk.
• Spinal Shock: Immediately after acute SCI, spinal shock commonly causes detrusor areflexia and retention. Recovery timing and subsequent bladder/sphincter patterns vary; repeat assessment is required.

3. Sacral & Infrasacral Lesions

• Etiologies: Conus medullaris injury, cauda equina syndrome, sacral agenesis, spina bifida / myelomeningocele, extensive pelvic surgery (abdominoperineal resection, radical hysterectomy).
• Pathophysiology: Direct destruction of the S2–S4 parasympathetic motor nucleus, Onuf's nucleus, or pelvic plexus peripheral nerves.
• Urodynamic Pattern: Detrusor Underactivity or Detrusor Acontractility with an Areflexic or Incompetent/Denervated Sphincter.
• Clinical Presentation: Absent bladder sensation, large post-void residual volumes, chronic retention, overflow incontinence, and progressive loss of bladder wall compliance due to collagen deposition.

---

3. Autonomic Dysreflexia (AD)

Autonomic dysreflexia is a medical emergency that can precipitate hypertensive encephalopathy, intracerebral hemorrhage, retinal detachment, myocardial infarction, and death.

                    [ NOXIOUS STIMULUS BELOW T6 ]
              (Distended Bladder / Blocked Catheter)
                                 │
                                 ▼
                   [ MASSIVE SYMPATHETIC SURGE ]
                     (Splanchnic Vasoconstriction)
                                 │
                 ┌───────────────┴───────────────┐
                 ▼                               ▼
      [ ACUTE BP ELEVATION     ]        [ BARORECEPTOR STIMULATION ]
      (SBP rise >20 mmHg from baseline)     (Vagus Nerve Activation)
                 │                               │
                 ▼                               ▼
     PALE, COLD, CLAMMY SKIN             BRADYCARDIA & FLUSHING
         (Below Lesion)                      (Above Lesion)

Definition & Pathophysiology

• In adults, a systolic rise >20 mmHg above the usual baseline may indicate AD; severe hypertension can develop, but a BP of 200/110 mmHg is not required.
• Occurs in individuals with spinal cord lesions at or above the T6 thoracic level (above the primary splanchnic sympathetic outflow).
• The Trigger: A noxious visceral or cutaneous sensory stimulus below the lesion—most commonly acute bladder distension, occluded urinary catheter, cystoscopy, or symptomatic UTI; secondary triggers include fecal impaction or acute surgical abdomen.
• Mechanism: Afferent visceral signals ascend through intact peripheral nerves into the isolated spinal cord, triggering an uninhibited, massive sympathetic reflex surge through the splanchnic vascular bed. This causes severe splanchnic vasoconstriction and life-threatening systemic hypertension.
• Brainstem Response: Carotid sinus and aortic arch baroreceptors detect hypertension and stimulate parasympathetic vagal output, causing reflex bradycardia. Descending inhibitory vasomotor signals cannot traverse the damaged spinal cord below T6. As a result, profound vasoconstriction persists unchecked below the lesion.

Clinical Presentation

• Above the Lesion Level: Pounding, severe throbbing headache, profuse diaphoresis, facial cutaneous flushing, nasal congestion, and possible bradycardia or tachycardia.
• Below the Lesion Level: Cold, pale, clammy skin, piloerection ("goosebumps"), and profound peripheral arteriolar vasoconstriction with malignant hypertension.

Emergency Stepwise Management Protocol

1. Sit the Patient Upright and Lower the Legs if possible. Obtain urgent assistance, measure BP and pulse every 1–2 minutes, and loosen constrictive clothing, binders and straps.
2. Control Marked Hypertension While Removing the Trigger: At systolic BP ≥150 mmHg, consider a rapid-onset, short-duration antihypertensive before catheter insertion/replacement. Follow the local AD protocol; nitrates must not be given after recent PDE5-inhibitor use. Oral immediate-release nifedipine is an alternative in appropriate patients; monitor for hypotension.
3. Check Bladder Drainage First:
   • Inspect the entire catheter system for kinks, incorrect position or an overfilled bag and correct these immediately. If necessary, gently test patency with 10–15 mL body-warm saline; stop if there is no drainage and replace a blocked catheter rather than repeatedly flushing it.
   • If no catheter is present, catheterize gently. Use 2% lidocaine jelly before insertion/replacement when available and allow approximately 3–5 minutes to act if feasible. Do not compress or tap the bladder.
4. Seek Other Triggers if AD Persists: Consider fecal impaction after bladder drainage. Persistent systolic BP ≥150 mmHg warrants pharmacological control before rectal examination; use topical anaesthetic and gentle examination/removal.
5. Reassess and Monitor: Check BP during and after drainage and after medication. Watch for recurrent AD and treatment-related hypotension; persistent severe hypertension or an unidentified trigger requires emergency evaluation.

---

4. Comprehensive Management of NLUTD

Hierarchy of Treatment Goals (EAU Guidelines)

1. Protect the Upper Urinary Tracts and preserve renal function.
2. Achieve or Maintain Continence.
3. Restore Lower Urinary Tract Function where possible.
4. Improve Quality of Life, accounting for disability, cognition, dexterity, caregiver support and patient preferences. Prevent AD in susceptible patients.

Urodynamic Risk Assessment

• Detrusor Leak Point Pressure (DLPP) is the lowest detrusor pressure at which leakage occurs without a detrusor contraction or increased abdominal pressure. The historical 40 cmH2O risk marker is not a universal safe/unsafe boundary; DLPP alone has insufficient sensitivity to assess upper-tract risk.
• Storage Pressures and Compliance: Sustained high filling pressures and low compliance are concerning. Assess the pressure-volume trace, NDO, DSD, reflux, upper-tract imaging and renal function together rather than applying universal end-filling <15 cmH2O or compliance >20–30 cutoffs.
• Follow-up: Repeat urodynamics to confirm treatment has made storage/emptying safer, and individualize lifelong renal surveillance. EAU suggests upper-tract ultrasound approximately every six months in high-risk patients.

Conservative & Emptying Modalities

• Clean Intermittent Self-Catheterization (CISC / CIC):
  • The preferred emptying method when a neurological patient cannot empty effectively and self- or caregiver catheterization is feasible; provide training and shared decision-making.
  • Performed 4 to 6 times daily; catheterization volume should not exceed 400 to 500 mL to prevent bladder wall overdistension and microvascular mucosal ischemia.
  • Select an appropriate catheter and teach atraumatic technique. Hydrophilic catheters are associated with fewer UTIs; catheter choice also depends on the patient, availability and preferences.
• Triggered Reflex Voiding / Crede Maneuver: Strongly discouraged in patients with DSD. Crede (abdominal compression) or Valsalva voiding generates dangerously high intravesical pressures against a contracted sphincter, accelerating upper tract destruction.

Pharmacological Management

• High-Dose Antimuscarinics: Standard first-line medical therapy to suppress neurogenic detrusor overactivity (NDO) and lower intravesical storage pressures (frequently requires doses above standard labeling under close specialist monitoring).
• Beta-3 Agonists: May improve neurogenic overactive-bladder symptoms without antimuscarinic burden. EAU advises against using them with the intention of reducing urodynamically proven NDO; symptom improvement does not establish safe storage pressures.

Intravesical OnabotulinumtoxinA (Botox)

• Standard Adult MS/SCI NDO Dose: 200 Units of onabotulinumtoxinA injected into the detrusor, conventionally across 30 sites avoiding the trigone. Use the protocol for the specific preparation; toxin units are not interchangeable.
• Reduces incontinence and NDO pressures and increases capacity; complete dryness is not assured. Reassess pressure control with urodynamics when indicated.
• Effects commonly last around nine months, with individual variation and repeat treatment when needed.
• Counsel about UTI, retention and possible AD; establish that intermittent catheterization can be performed if required.

Bladder Augmentation (Enterocystoplasty)

• Indicated in refractory high-pressure neurogenic bladders with compromised compliance, severe NDO, or deteriorating upper tracts despite maximal medical and Botox therapy.
• Surgical Technique: "Clam" cystoplasty. The bladder is bivalved in the coronal plane down to the bladder neck; a 25–30 cm detubularized, reconfigured segment of ileum (or sigmoid colon) is anastomosed onto the bivalved bladder as a low-pressure, high-compliance patch.
• Continent Catheterizable Stoma:
  • Often constructed concurrently if the native urethra is unsalvageable or inaccessible (e.g., tetraplegic patients or female wheelchair users).
  • Mitrofanoff Appendicovesicostomy: The vermiform appendix is isolated on its mesoappendix, implanted submucosally into the augmented bladder using a submucosal continence tunnel, and matured as an umbilical cutaneous stoma.
  • Monti Procedure: Reconfigured, retubularized short ileal segment utilized when the appendix is absent or unsuitable.
• Long-Term Complications & Lifelong Surveillance:
  • Bladder calculi (10% to 30%), recurrent mucus plugging, hyperchloremic metabolic acidosis, and spontaneous bladder perforation (presents with acute peritonitis; requires emergency laparotomy).
  • Malignancy Risk: Malignancy can develop after a long latency, often over 10 years. Maintain lifelong follow-up of symptoms, renal function, electrolytes and urinary-tract imaging. Hematuria, unexplained recurrent symptomatic UTI or pain warrants investigation including cystoscopy; routine annual cystoscopy from year 10 is not a universal guideline requirement.

---

5. Neurological Lesion Level, Urodynamic Pattern & Management Matrix